BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at Wall Street Zen

BioXcel Therapeutics (NASDAQ:BTAI) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Monday. HC Wainwright lowered their price target on BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Rodman & Renshaw initiated coverage on BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price target on the stock. Finally, Zacks Research raised BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioXcel Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $11.00.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $1.06 on Friday. The stock’s 50-day simple moving average is $1.39 and its 200 day simple moving average is $1.74. The company has a market cap of $28.70 million, a P/E ratio of -0.16 and a beta of 0.30. BioXcel Therapeutics has a 52-week low of $1.01 and a 52-week high of $8.08.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.58). As a group, equities analysts predict that BioXcel Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioXcel Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in BioXcel Therapeutics by 27.7% during the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after purchasing an additional 6,120 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of BioXcel Therapeutics by 38.5% during the third quarter. Jones Financial Companies Lllp now owns 36,000 shares of the company’s stock worth $97,000 after buying an additional 10,000 shares in the last quarter. State Street Corp increased its holdings in shares of BioXcel Therapeutics by 19.9% during the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after buying an additional 10,500 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in BioXcel Therapeutics in the second quarter valued at $27,000. Finally, HRT Financial LP acquired a new stake in BioXcel Therapeutics in the fourth quarter valued at $28,000. 30.68% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.